We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Benign prostat hiperplazisi medikal tedavilerinin seksüel fonksiyonlar üzerindeki etkisi.
- Authors
Erten, Kadir Şerefhan; Karabacak, Nihat; Polat, Fazli; Atan, Ali
- Abstract
Benign Prostatic Hyperplasia (BPH) generally presents with Lower Urinary Tract Complaints (LUTS). Alpha blockers, 5-alpha reductase inhibitors (5AR-i), phosphodiesterase-5 inhibitors (PDE 5i) drugs are recommended and commonly used medications for the treatment of BPH. While forming a treatment plan and choosing the most suitable medication, the severity of complaints and prostate volume should be considered as well as the patient's demands and expectations. In uptodate literature, phosphodiesterase 5 inhibitors (PDE 5i) stand out as a suitable option for patients who prioritize normal sexual function. Combination of PDE 5i and Alpha blockers are recommended in patients with a prostate volume below 40 ml. Combination of PDE 5i and 5-ARi drugs are usually preferred in patients with a prostate volume larger than 40 ml and in avoiding sexual dysfunction. Phosphodiesterase 5i and Antimuscarinic drugs combination should be considered when Tadalafil monotherapy does not provide sufficient improvement in storage complaints.
- Publication
Androloji Bülteni (Andrology Bullettin), 2024, Vol 26, Issue 2, p129
- ISSN
1304-6861
- Publication type
Article
- DOI
10.24898/tandro.2024.69862